Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 12:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–11 of 11 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Repurposed Therapeutics, Inc. Clear all
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers

DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion Sickness

NCT04219982
View directory record Official record
Conditions
Motion Sickness
Interventions
DPI-386 Nasal Gel, DPI-386 Placebo Nasal Gel, Transderm Scop®
Drug
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Oct 1, 2026, 12:32 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

The Prevention and Treatment of Nausea Associated With Motion Sickness

NCT03986905
View directory record Official record
Conditions
Motion Sickness
Interventions
Scopolamine Nasal Gel, Placebo
Drug · Other
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 1, 2026, 12:32 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Nasal Gel Under Military Operational Conditions for the Prevention of Nausea Associated With Motion Sickness

NCT04272255
View directory record Official record
Conditions
Motion Sickness
Interventions
scopolamine HBr, Transdermal Scopolamine
Drug
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 1, 2026, 12:32 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion

NCT04947423
View directory record Official record
Conditions
Motion Sickness
Interventions
DPI-386 Nasal Gel, Placebo
Drug
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2021 · Synced Oct 1, 2026, 12:32 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness

NCT04184115
View directory record Official record
Conditions
Motion Sickness
Interventions
DPI-386 Nasal Gel, Placebos
Drug
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 1, 2026, 12:32 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance

NCT05852730
View directory record Official record
Conditions
Motion Sickness, Space, Motion Simulation, Parabolic Flight
Interventions
DPI-386 Nasal Gel, Other (e.g., promethazine, meclizine)
Drug
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 1, 2026, 12:32 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance

NCT05886660
View directory record Official record
Conditions
Motion Sickness, Space, Motion Sickness, Sea Sickness
Interventions
DPI-386 Nasal Gel, Placebo Nasal Gel
Drug
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2024 · Synced Oct 1, 2026, 12:32 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Scopolamine in Healthy Volunteers

NCT03874130
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Scopolamine
Drug
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 1, 2026, 12:32 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects

NCT03988530
View directory record Official record
Conditions
Motion Sickness
Interventions
Scopolamine, Placebo Nasal Gel
Drug · Other
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
55 Years and older
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 1, 2026, 12:32 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion

NCT05548270
View directory record Official record
Conditions
Motion Sickness
Interventions
DPI-386 Nasal Gel, Placebo
Drug
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
503 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 1, 2026, 12:32 PM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Pharmacokinetic and Efficacy Profile Intranasal Scopolamine Spray

NCT02155309
View directory record Official record
Conditions
Motion Sickness
Interventions
Scopolamine, Placebo
Drug
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 1, 2026, 12:32 PM EDT